MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY:

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY:"

Transcription

1 Important note Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit plan contains its own specific provisions for coverage and exclusions. Not all benefits that are determined to be medically necessary will be covered benefits under the terms of your benefit plan. You need to consult the Evidence of Coverage to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and your plan of benefits, the provisions of your benefits plan will govern. However, applicable state mandates will take precedence with respect to fully insured plans and self-funded non-erisa (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, Federal mandates will apply to all plans. With respect to Senior Care members, this policy will apply unless Medicare policies extend coverage beyond this Medical Policy & Criteria Statement. Senior Care policies will only apply to benefits paid for under Medicare rules, and not to any other health benefit plan benefits. CMS's Coverage Issues Manual can be found on the CMS website. SERVICE: PRIOR AUTHORIZATION: Required. POLICY: Continuous subcutaneous insulin infusion and related drugs/supplies are covered as medically reasonable and necessary for the treatment of diabetic patients who meet ALL of the criteria (1-4) below. (Insulin for insulin pumps requires a prescription and must be obtained at a plan pharmacy): (Adapted from CMS NCD ) 1. Patients must meet EITHER Criterion A or B as follows: Criterion A: The patient must meet ALL of the following: a. Completed a comprehensive diabetes education program, AND b. Has been on a program of multiple daily injections of insulin (i.e., at least 3 injections per day), with frequent self-adjustments of insulin doses for at least 6 months prior to initiation of the insulin pump, AND c. Documented frequency of glucose self-testing an average of at least 4 times per day during the 2 months prior to initiation of the insulin pump, AND d. Meets ONE or MORE of the following criteria while on the multiple daily injection regimen: Glycosylated hemoglobin level (HbAlc) > 7.0 percent; History of recurring hypoglycemia; Wide fluctuations in blood glucose before mealtime; Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dl; or, History of severe glycemic excursions. For pediatric patients: member requiring very low insulin doses that cannot be safely delivered with insulin injection therapy Criterion B: The patient with diabetes is already on a pump on effective date of SWHP coverage, and has documented frequency of glucose self-testing an average of at least 4 times per day. Page 1 of 5

2 2. The patient must be insulinopenic as evidenced by the updated fasting C-peptide testing requirement, a positive beta cell autoantibody test (Islet Cell Cytoplasmic Autoantibodies), OR, for lines of business other than SeniorCare, a history of diabetic ketoacidosis. Fasting C-peptide testing requirement: Has a fasting C-peptide level that is less than or equal to 110% of the lower limit of normal of the laboratory's measurement method. For patients with renal insufficiency and creatinine clearance (actual or calculated from age, gender, weight, and serum creatinine) 50 ml/minute, insulinopenia is defined as a fasting C-peptide level that is less than or equal to 200% of the lower limit of normal of the laboratory's measurement method. Fasting C-peptide levels will only be considered valid with a concurrently obtained fasting glucose 225 mg/dl. Levels only need to be documented once in the medical records. 3. Continued coverage of the insulin pump would require that the patient be seen and evaluated by the treating physician at least every 3 months. 4. The pump must be ordered by and follow-up care of the patient must be managed by an endocrinologist physician who manages multiple patients with CSII and who works closely with a team including nurses, diabetes educators, and dietitians who are knowledgeable in the use of CSII. An implantable insulin pump therapy may be medically necessary for patients with type 1 or type 2 diabetes mellitus who have not achieved adequate glycemic control with intensive SC insulin therapy or an external insulin pump. (See first exclusion below.) Replacement of an insulin pump is covered once every 4 years, or when the insulin pump malfunctions, is no longer under warranty, and cannot be repaired. An implanted infusion pump for the infusion of insulin to treat diabetes is NOT covered by Medicare because the data do not demonstrate that the pump provides effective administration of insulin. Chronic intermittent intravenous insulin therapy (CIIIT) also referred to as metabolic activation therapy (MAT), or pulsatile intravenous insulin therapy (PIIT) is NOT covered because it is considered experimental/investigational or unproven. Supplies or accessories not required for the functioning of the insulin pump, such as alcohol, alcohol wipes, carrying cases, clips, pouches, shower packs, etc., are NOT covered. Combined or integrated continuous subcutaneous insulin infusion pump and standard fingerstick blood glucose monitoring (CSII-BGM) system (e.g., Omnipod Starter Kit [pods and Personal Diabetes Manager]) are covered as medically necessary for the management of type 1 diabetes mellitus if the member meets criteria for CSII, or member was already on a CSII device on the effective date of SWHP coverage. Page 2 of 5

3 Replacement of an insulin pump is covered once every 4 years, or when the insulin pump malfunctions, is no longer under warranty, and cannot be repaired. Supplies or accessories not required for the functioning of the insulin pump, such as alcohol, alcohol wipes, carrying cases, clips, pouches, shower packs, etc., are NOT covered. Continuous glucose monitoring systems (CGMS) may be medically necessary when such monitoring is needed to detect trends and patterns in glucose levels over time in order to optimize glycemic control and reduce incidences of hyperglycemia and hypoglycemia in insulin-dependent diabetics. The following criteria must be met: 1. Member requires insulin injections 3 or more times per day or use of an insulin pump for maintenance of blood sugar control; AND 2. Member is capable of using a long-term continuous glucose monitoring system; AND 3. Member meets at least one of the following criteria despite adherence to a physician ordered diabetic treatment plan and compliance with at least four times per day self-monitoring and multiple alterations in insulin administration regimens: Member has been unable to achieve optimum glycemic control as defined by the current version of the American Diabetes Association Standards of Medical Care in Diabetes 1; OR Member has experienced hypoglycemia unawareness; OR Member has experienced recurring episodes of severe hypoglycemia (<50 mg/dl). Coverage for members already on a CGMS device on the effective date of SWHP coverage may be continued after medical review. Short-term use (less than 7 days) of continuous glucose monitoring devices may be considered medically necessary when there is inadequate glycemic control despite compliance with frequent (at least 4x/day) self-monitoring, and: 1. Poor control is in spite of compliance with multiple alterations in self-monitoring and insulin administration regimens, as evidenced by fasting hyperglycemia (>150 mg/dl) or recurring episodes of severe hypoglycemia (<50 mg/dl); and 2. Insulin injections are required 3 or more times per day, or use of an insulin pump is required for maintenance of blood sugar control; and 3. Results are monitored and interpreted under supervision of a physician. Authorizations for short-term use are limited to 3 times during the calendar year. NOT considered medically necessary for individuals with type 2 diabetes as there is limited evidence that the use of such monitoring leads to improved glycemic control. NOT considered medically necessary for pregnant women with gestational diabetes (not known to be diabetic prior to pregnancy) as there is limited evidence to suggest that the use Page 3 of 5

4 of CGMS in these patients results in a reduction in undetected hyperglycemia and nocturnal hypoglycemic events. Combined or integrated continuous subcutaneous insulin infusion and blood glucose monitoring system that includes a continuous blood glucose monitor (CBGM) are covered as medically necessary for long-term use in the treatment of ANY of the following: Type 1 diabetic age 25 years or older Type 1 diabetic age 24 years or younger with recurrent, severe hypoglycemic events (i.e., blood glucose 50mg/dL) despite appropriate modifications in insulin therapy and compliance with frequent self-monitoring of blood glucose (i.e., at least four times daily) Type 2 diabetic with recurrent, severe hypoglycemic events (i.e., blood glucose < 50mg/dL) despite appropriate modifications in insulin therapy, and compliance with frequent selfmonitoring of blood glucose (i.e., at least four times daily) and EITHER of the following: Fasting C-peptide level 110% of the lower limit of normal of the laboratory s measurement method AND a concurrently obtained fasting glucose 225 mg/dl Renal insufficiency with a creatinine clearance (actual or calculated from age, gender, weight and serum creatinine) 50 ml/minute AND a fasting C-peptide level 200% of the lower limit of normal of the laboratory s measurement method This coverage is NOT available for Senior Care line of business General information: SWHP covers as medically necessary DME, the supplies required for the proper use of a medically necessary insulin pump including custom-designed batteries and power supplies. However, off-theshelf batteries that can also be used to power non-medical equipment are not considered DME and are therefore not covered. SWHP does not cover additional software or hardware required for downloading data to a personal computer to aid in self-management of diabetes mellitus because it is considered a convenience item and not medically necessary. SWHP does not cover a transdermal insulin delivery system (e.g., V-Go Disposable Insulin Delivery Device) because it is considered experimental, investigational or unproven. OVERVIEW: An external insulin pump is a device that delivers insulin subcutaneously. The insulin is delivered in a programmed and controlled manner and eliminates the need for the patient to selfinject insulin. The main goal in using an insulin pump is to achieve near normal blood glucose levels in order to prevent both acute and chronic complications of diabetes and prevent dangerous episodes of low blood sugar. MANDATES: N/A CODES: HCPCS Codes: A4230 Infusion set for external insulin pump, non-needle cannula type A4231 Infusion set for external insulin pump, needle type A4232 Syringe with needle for external insulin pump, sterile, 3cc Page 4 of 5

5 CPT Not Covered: ICD9 codes: ICD9 Not covered: A9274 External ambulatory delivery system, disposable, each, includes all supplies and accessories E0784 External ambulatory infusion pump, insulin E1399 Durable medical equipment, miscellaneous K0552 Supplies for external drug infusion pump, syringe type cartridge, sterile, each S9145 Insulin pump initiation, instruction in initial use of pump (pump not included) 250.xx CMS: See NCD effective 2/18/2005 POLICY HISTORY: Status Date Action New 8/1/2010 New policy Reviewed 12/2/2011 Reviewed. Reviewed 12/6/2012 Reviewed. Extensively revised. Reviewed 2/28/2013 Reviewed and revised pediatric section. REFERENCES: The following scientific references were utilized in the formulation of this medical policy. SWHP will continue to review clinical evidence related to this policy and may modify it at a later date based upon the evolution of the published clinical evidence. Should additional scientific studies become available and they are not included in the list, please forward the reference(s) to SWHP so the information can be reviewed by the Medical Coverage Policy Committee (MCPC) and the Quality Improvement Committee (QIC) to determine if a modification of the policy is in order. 1. Centers for Medicare & Medicaid Services Medicare Coverage Database LCD for External Infusion Pumps (L5044). Revision 01 /01/ Eugster EA, Francis G and the Lawson-Wilkins Drug and Therapeutics Committee. Position Statement: Continuous Subcutaneous Insulin Infusion in Very Young Children with Type 1 Diabetes. Pediatrics 2006 Oct:1 1 8(4): Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV. Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children with Type 1 Diabetes: A Follow-up Report. Pediatrics 2004 Dec;1 14(6): Kaufman FR, Halvorson M, Carpenter S, Devoe D, Pitukcheewanont P. Insulin Pump Therapy in Young Children with Diabetes. Diabetes Spectrum 2001;14(2): Cummins E, Royle P, Snaith A, et al.(2010) Clinical effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Asses, 2010; 14: Pickup JC.(2012) Insulin-Pump Therapy for Type 1 Diabetes-Mellitus. New Engl J Med, 2012; 266: Page 5 of 5

Insulin Infusion Pumps

Insulin Infusion Pumps Medical Coverage Policy Insulin Infusion Pumps EFFECTIVE DATE: 09/01/2004 POLICY LAST UPDATED: 08/06/2013 OVERVIEW The policy addresses insulin infusion pumps that are worn externally and those that are

More information

Criteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps)

Criteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps) Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 05/15 Revision Date(s): 05/2015 Developed By: Medical Criteria Committee 06/24/2015 External Infusion Insulin Pumps Page 1 of

More information

External Insulin Pumps Corporate Medical Policy

External Insulin Pumps Corporate Medical Policy External Insulin Pumps Corporate Medical Policy File name: External Insulin Pumps File code: UM.DME.02 Origination: 4/2006 Last Review: 02/2014 (ICD-10 remediation only) Next Review: 10/2014 Effective

More information

Clinical Policy Guideline

Clinical Policy Guideline Policy Title: External Insulin Infusion Pump Effective Date: 11/29/2001 Clinical Policy Guideline Date Reviewed: 07/22/10, 12/13/10, 02/18/11, 09/11, 01/23/13, 06/18/14, 07/29/15 I. DEFINITION An external

More information

ADMINISTRATIVE POLICY AND PROCEDURES MedStar Family Choice

ADMINISTRATIVE POLICY AND PROCEDURES MedStar Family Choice ADMINISTRATIVE POLICY AND PROCEDURES MedStar Family Choice Policy #: 1405 Subject: Continuous Glucose Effective Date: 12/01/2012 Monitoring Devices Revision Dates: 10/13, 10/14 Section: Care Management

More information

MEDICAL POLICY POLICY TITLE DIABETIC SELF-MANAGEMENT TRAINING PROGRAM POLICY NUMBER MP- 2.076

MEDICAL POLICY POLICY TITLE DIABETIC SELF-MANAGEMENT TRAINING PROGRAM POLICY NUMBER MP- 2.076 Original Issue Date (Created): July 1, 2005 Most Recent Review Date (Revised): Effective Date: May 24, 2011 August 31, 2011- RETIRED I. POLICY Initial diabetic self-management training (DSMT) may be considered

More information

Clinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps

Clinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps Clinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps Clinical Policy Number: 06.02.01 Effective Date: March 1, 2014 Initial Review Date: Nov. 20 th, 2013 Most Recent Review

More information

Clinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps

Clinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps Clinical Policy Title: Disposable Continuous Subcutaneous Insulin Infusion Pumps Clinical Policy Number: 06.02.01 Effective Date: March 1, 2014 Initial Review Date: Nov. 20, 2013 Most Recent Review Date:

More information

CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES

CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES Protocol: END002 Effective Date: 6/1/2015 Table of Contents Page COMMERCIAL COVERAGE RATIONALE... 1 MEDICARE COVERAGE RATIONALE...

More information

sad EFFECTIVE DATE: POLICY LAST UPDATED:

sad EFFECTIVE DATE: POLICY LAST UPDATED: Medical Coverage Policy Glucose Monitoring Systems sad EFFECTIVE DATE: 12 01 2014 POLICY LAST UPDATED: 11 18 2014 OVERVIEW This policy addresses several methods of monitoring blood glucose: the glucometer,

More information

Medical Policy Insulin Pumps

Medical Policy Insulin Pumps Medical Policy Insulin Pumps Document Number: 027 Authorization required Insulin Pumps & supplies Notification within 24 hours of service or next business day No Prior Authorization Not covered Pulsatile

More information

Medical Coverage Policy Glucose Monitoring Systems sad

Medical Coverage Policy Glucose Monitoring Systems sad Medical Coverage Policy Glucose Monitoring Systems sad EFFECTIVE DATE: 03 03 2009 POLICY LAST UPDATED: 01 17 2012 OVERVIEW This policy addresses several methods of monitoring blood glucose: the glucometer,

More information

Medical Policy Insulin Delivery Devices

Medical Policy Insulin Delivery Devices Medical Policy Insulin Delivery Devices Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization Information

More information

When services are covered 1 2 We cover insulin pumps and insulin pump supplies, in accordance with the Massachusetts Mandate, Chapter 175.

When services are covered 1 2 We cover insulin pumps and insulin pump supplies, in accordance with the Massachusetts Mandate, Chapter 175. MEDICAL POLICY Policy #: 332 Original policy date: 4/96 Page: 1 of 8 Revised date: 6/27/2014 Title Insulin Delivery Devices Pumps, Pens, and Jet Injectors Related policies: Diabetic Supplies, #202 CGMS,

More information

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 10/24/2014 Section: DME Place(s)

More information

Clinical Policy Title: Insulin Infusion Therapy (Insulin Pumps)

Clinical Policy Title: Insulin Infusion Therapy (Insulin Pumps) Clinical Policy Title: Insulin Infusion Therapy (Insulin Pumps) Clinical Policy Number: 06.02.01 Effective Date: July 1, 2015 Initial Review Date: November 20, 2013 Most Recent Review Date: April 15, 2015

More information

MEDICAL POLICY No R6 CONTINUOUS GLUCOSE MONITORING

MEDICAL POLICY No R6 CONTINUOUS GLUCOSE MONITORING CONTINUOUS GLUCOSE MONITORING Effective Date: May 3, 2013 Review Dates: 2/03, 1/04, 7/04, 7/05, 6/06, 6/07, 2/08, 8/08, 8/09, 4/10, 4/11, 4/12, 4/13, 5/14, 5/15, 5/16 Date Of Origin: February 26, 2003

More information

Medical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10, 01/11, 01/12

Medical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10, 01/11, 01/12 Continuous or Intermittent Monitoring of Glucose in Interstitial (10120) Medical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10,

More information

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/19/2015 06/19/2016 06/19/2015 Policy Name Policy Number Insulin Infusion Pump Therapy for Diabetes

More information

Medical Policy Continuous Glucose Monitors

Medical Policy Continuous Glucose Monitors Medical Policy Continuous Glucose Monitors Document Number: 025 Authorization required Long Term Continuous Glucose Monitors & Sensors Notification within 24 hours of service or next business day No Prior

More information

Overview. Provider Qualifications

Overview. Provider Qualifications Overview Diabetes self management training (DSMT) is a collaborative process through which patients with diabetes gain knowledge and skills needed to modify behavior and successfully manage the disease

More information

Chapter. CPT only copyright 2009 American Medical Association. All rights reserved. 15Diabetic Equipment and Supplies

Chapter. CPT only copyright 2009 American Medical Association. All rights reserved. 15Diabetic Equipment and Supplies Chapter 15Diabetic Equipment and Supplies 15 15.1 Enrollment...................................................... 15-2 15.2 Benefits, Limitations, and Authorization Requirements......................

More information

Get Primed on Pumps: A beginners guide to Insulin Pump Therapy

Get Primed on Pumps: A beginners guide to Insulin Pump Therapy Get Primed on Pumps: A beginners guide to Insulin Pump Therapy Advantages of insulin pump therapy There are many advantages to using an insulin pump. Anyone can do it with the right training and support.

More information

The Department of Vermont Health Access Medical Policy

The Department of Vermont Health Access Medical Policy State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 [Phone] 802-879-5903 Williston, VT 05495-2807 [Fax] 802-879-5963 www.dvha.vermont.gov Agency of Human Services The Department

More information

CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES

CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES MEDICAL POLICY CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES Policy Number: CS024.E Effective Date: April 1, 2016 Table of Contents COVERAGE RATIONALE APPLICABLE CODES.. DESCRIPTION

More information

Alternative method for delivering insulin using continuous subcutaneous insulin infusion (CSII) open loop system

Alternative method for delivering insulin using continuous subcutaneous insulin infusion (CSII) open loop system ISHP Spring CE Conference April 12, 2015 St. Luke s Medical Center Randi Lynn Griffiths, PharmD Clinical outpatient pharmacist Boise VA Medical Center Boise, Idaho Alternative method for delivering insulin

More information

CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES

CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES MEDICAL POLICY CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES Policy Number: 2015T0347R Effective Date: April 22, 2015 Table of Contents BENEFIT CONSIDERATIONS COVERAGE RATIONALE

More information

Diabetes Outpatient Self-Management Training (NCD 40.1)

Diabetes Outpatient Self-Management Training (NCD 40.1) Policy Number 40.1 Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 02/11/2015 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare

More information

Continuous Subcutaneous Insulin Infusion (CSII)

Continuous Subcutaneous Insulin Infusion (CSII) IMPORTANCE OF FOCUS CSII (Insulin pumps) have been used for more than 35 years. In the U.S. in 2005, the level of insulin pump penetration was estimated at 20 to 30% in patients with type 1 diabetes mellitus

More information

MEDICAL COVERAGE POLICY. SERVICE: Bariatric (Weight Loss) Surgery Policy Number: 053 Effective Date: 5/27/2014 Last Review: 4/24/2014

MEDICAL COVERAGE POLICY. SERVICE: Bariatric (Weight Loss) Surgery Policy Number: 053 Effective Date: 5/27/2014 Last Review: 4/24/2014 Page 1 of 6 MEDICAL COVERAGE POLICY Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid

More information

( Self-measurement of blood glucose, SMBG )

( Self-measurement of blood glucose, SMBG ) 2006 17 123-127 ( Diabetes mellitus ) ( Continuous glucose monitor system, ) ( Self-measurement of blood glucose, SMBG ) DCCT(Diabetes Control and Complications Trial ) UKPDS ( U.K. Prospective Diabetes

More information

A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Basal Dosing

A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Basal Dosing Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients Allen B.,

More information

An Overview of Medicare Covered Diabetes Supplies and Services

An Overview of Medicare Covered Diabetes Supplies and Services News Flash - Understanding the Remittance Advice: A Guide for Medicare Providers, Physicians, Suppliers, and Billers serves as a resource on how to read and understand a Remittance Advice (RA). Inside

More information

A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Bolus Dosing

A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Bolus Dosing Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients Allen B.,

More information

Frequently Asked Questions - Beneficiary

Frequently Asked Questions - Beneficiary Newfoundland and Labrador Prescription Drug Program Department of Health and Community Services Frequently Asked Questions - Beneficiary 1. What is the purpose of Blood Glucose Test Strips? Blood Glucose

More information

[ ] POCT glucose Routine, As needed, If long acting insulin is given and patient NPO, do POCT glucose every 2 hours until patient eats.

[ ] POCT glucose Routine, As needed, If long acting insulin is given and patient NPO, do POCT glucose every 2 hours until patient eats. Glycemic Control - Insulin Infusion NOTE: For treatment of Diabetic Ketoacidosis or Hyperglycemic Hyperosmolar Syndrome please go to order set named Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

Basal and Bolus Insulin 7/16/2014. Jackie Aday RN, BSN, CDE Jeni Neighbors RN, BSN, CDE. BASAL: Small amount of insulin infused every few minutes

Basal and Bolus Insulin 7/16/2014. Jackie Aday RN, BSN, CDE Jeni Neighbors RN, BSN, CDE. BASAL: Small amount of insulin infused every few minutes Jackie Aday RN, BSN, CDE Jeni Neighbors RN, BSN, CDE Insulin Pump Therapy Open looped system in which a small amount of insulin is continuously infused through a cannula or needle (basal rate) Larger doses

More information

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes.

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes. PROTOCOL Clinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes. A. This the revised protocol (April 2002) B. Review team Contact for correspondence: Dr Jill Colquitt

More information

Asian Journal of Phytomedicine and Clinical Research Journal home page:

Asian Journal of Phytomedicine and Clinical Research Journal home page: Research Article CODEN: AJPCFF ISSN: 2321 0915 Asian Journal of Phytomedicine and Clinical Research Journal home page: www.ajpcrjournal.com A COMPARITIVE STUDY FOR THE ASSESSMENT OF QUALITY OF LIFE USING

More information

Contractor Information. LCD Information. Local Coverage Determination (LCD): HbA1c (L32939) Contract Number 11202

Contractor Information. LCD Information. Local Coverage Determination (LCD): HbA1c (L32939) Contract Number 11202 Local Coverage Determination (LCD): HbA1c (L32939) Contractor Information Contractor Name Palmetto GBA opens in new window Contract Number 11202 Contract Type MAC - Part B LCD Information Document Information

More information

Protocol. Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid

Protocol. Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Continuous or Intermittent Monitoring of Glucose in Interstitial (10120) Medical Benefit Effective Date: 07/01/15 Next Review Date: 03/17 Preauthorization Yes Review Dates: 07/07, 07/08, 07/09, 01/10,

More information

Starting patients on the V-Go Disposable Insulin Delivery Device

Starting patients on the V-Go Disposable Insulin Delivery Device Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate

More information

MANAGEMENT OF TYPE - 1 DIABETES MELLITUS

MANAGEMENT OF TYPE - 1 DIABETES MELLITUS MANAGEMENT OF TYPE - 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria

More information

Insulin Pump Therapy in children & Adolescents. Dr. Abdulmoein Al-Agha, MBBS,DCH, FRCP(UK) Pediatric Endocrinologist

Insulin Pump Therapy in children & Adolescents. Dr. Abdulmoein Al-Agha, MBBS,DCH, FRCP(UK) Pediatric Endocrinologist Insulin Pump Therapy in children & Adolescents Dr. Abdulmoein Al-Agha, MBBS,DCH, FRCP(UK) Pediatric Endocrinologist Insulin The most powerful agent we have to control glucose Banting and Best The Miracle

More information

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die

More information

Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US

Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES Jo M. Kendrick, APN BC, CDE jkendric@utmck.edu Describe indications and contraindications for insulin pump use in hospitalized patients Differentiate

More information

Glucose Tolerance Testing

Glucose Tolerance Testing Glucose Tolerance Testing PROTOCOLS FOR PERFORMING GLUCOSE TOLERANCE TESTS INTRODUCTION Described in this section are the sample requirements, patient preparation instructions, dosages of substances to

More information

Technological Advances in Diabetes Management. Patti Duprey, MS, APRN

Technological Advances in Diabetes Management. Patti Duprey, MS, APRN Technological Advances in Diabetes Management Patti Duprey, MS, APRN 22nd Annual Northeast Regional Nurse Practitioner Conference May 6-8, 2015 DISCLOSURES Speakers Bureau for Sanofi Pasteur and Janssen.

More information

Insulin pump therapy aiming for better blood glucose control in people with type 1 diabetes

Insulin pump therapy aiming for better blood glucose control in people with type 1 diabetes Insulin pump therapy aiming for better blood glucose control in people with type 1 diabetes The Guy s and St Thomas NHS Foundation Trust insulin pump service is provided by a multidisciplinary team consisting

More information

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:

tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden: tips Top International Publications Selection Insulin Pump Users Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated Patients with TD Population Study of Pediatric

More information

ROYAL HOSPITAL FOR WOMEN

ROYAL HOSPITAL FOR WOMEN ROYAL HOSPITAL FOR WOMEN LOCAL OPERATING PROCEDURE CLINICAL POLICIES, PROCEDURES & GUIDELINES Approved by Quality & Patient Safety Committee 17 April 2014 INSULIN INFUSION PROTOCOL INSULIN DEXTROSE INFUSION

More information

The table below logs the history of the steps in development of the document.

The table below logs the history of the steps in development of the document. Paediatric Insulin Pumps Version: 0.4 Committee Approved by: Clinical Cabinet Date Approved 5 February 2014 Author: Responsible Directorate: Janet Wilson Strategy and Commissioning (Children s) Date issued:

More information

Algorithms for Glycemic Management of Type 2 Diabetes

Algorithms for Glycemic Management of Type 2 Diabetes KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association

More information

Name Date. Doctor. Usual times to test glucose at school Extra tests (check those that apply) before exercise after exercise other (explain)

Name Date. Doctor. Usual times to test glucose at school Extra tests (check those that apply) before exercise after exercise other (explain) Appendix A SAMPLE IHP Name Date Phone numbers Blood glucose Hypoglycemia Hyperglycemia Insulin Parent/guardian#1 Work Home Parent/guardian#2 Work Home Other emergency contact Doctor Usual times to test

More information

Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care

Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage

More information

Improving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge

Improving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge Improving drug prescription in elderly diabetic patients FRANCESC FORMIGA Hospital Universitari de Bellvitge High prevalence, but also increases the incidence. The older the patients, the higher the percentages

More information

CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES

CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES Oxford UnitedHealthcare Oxford Clinical Policy CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES Policy Number: DIABETIC 010.20 T2 Effective Date: August 1, 2016 Table of Contents

More information

SARASOTA MEMORIAL HOSPITAL

SARASOTA MEMORIAL HOSPITAL SARASOTA MEMORIAL HOSPITAL TITLE: NURSING PROCEDURE MANAGEMENT OF PATIENT S OWN INSULIN PUMP/CONTINUOUS SUBCUTANEOUS INSULIN INFUSION PUMP (dia13) DATE: REVIEWED: PAGES: 08/84 10/15 1 of 7 PS1094 ISSUED

More information

Insulin Delivery Options: Inhale, Inject, and Infuse. Traci Evans, A.N.P., B.C.-A.D.M. Nurse Practitioner The Diabetes Center Ocean Springs, MS

Insulin Delivery Options: Inhale, Inject, and Infuse. Traci Evans, A.N.P., B.C.-A.D.M. Nurse Practitioner The Diabetes Center Ocean Springs, MS Insulin Delivery Options: Inhale, Inject, and Infuse Traci Evans, A.N.P., B.C.-A.D.M. Nurse Practitioner The Diabetes Center Ocean Springs, MS Objectives Identify three ways patients are able to utilize

More information

Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus

Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus Louis Haenel, IV, DO, FACOI, FACE Endocrinology Roper Hospital Charleston, SC Dr. Louis Haenel IV has disclosed

More information

School Year 20 / 20. Diabetes Health Care Plan for Southgate Schools

School Year 20 / 20. Diabetes Health Care Plan for Southgate Schools School Year 20 / 20 Diabetes Health Care Plan for Southgate Schools Diabetes Medical Management Plan, Initialized Healthcare Plan and Physician Orders Part A: Contact Information must be completed by the

More information

Blood Glucose Monitoring Basics

Blood Glucose Monitoring Basics Blood glucose (BG) monitoring is a critical aspect of diabetes management and, for patients using insulin, the purpose is robust. A patient s insulin dose design and adjustment are based on glycemic patterns

More information

CLINICAL PRACTICE GUIDELINE

CLINICAL PRACTICE GUIDELINE CLINICAL PRACTICE GUIDELINE Procedure: Diabetes Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014 PURPOSE:

More information

CLINICAL PERFORMANCE OF CONTINUOUS GLUCOSE MONITORING SYSTEM IN TYPE 1 DIABETICS

CLINICAL PERFORMANCE OF CONTINUOUS GLUCOSE MONITORING SYSTEM IN TYPE 1 DIABETICS Department of Endocrinology, Diabetes and Metabolic Disorders, School of Medicine, Sv. Kiril i Metodij University, Bihaæka 3-2-41, MK-1000 Skopje, Macedonia Original Scientific Paper Received: October

More information

The Joint Commission Advanced DSC Certification for Inpatient Diabetes Care

The Joint Commission Advanced DSC Certification for Inpatient Diabetes Care The Joint Commission Advanced DSC Certification for Inpatient Diabetes Care November 12, 2013 Caroline Isbey RN, MSN, CDE Associate Director Teresa Gomez Associate Project Director Specialist-SSM Carol

More information

Description. Comprehensive Education Courses Take Control Now! (2 Hour Session Billed to Insurance)

Description. Comprehensive Education Courses Take Control Now! (2 Hour Session Billed to Insurance) The University of Maryland Diabetes Network offers the latest available therapies, clinical trials and custom tailored care plans just for you. Education is a key component to living with and managing

More information

What the quality statement means for each audience

What the quality statement means for each audience Standard 17 All patients with type 1 diabetes should have access to an experienced multidisciplinary team, including expertise in insulin pumps and continuous glucose monitoring (CGMS) when required. Key

More information

Insulin Pump Therapy

Insulin Pump Therapy Introduction The first insulin pumps, or continuous subcutaneous insulin infusion systems (CSII), were introduced in 1976. These early pumps were the size of a backpack and were unreliable. Since then,

More information

Lead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:

Lead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of: Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus

More information

ADVANTAGES AND DISADVANTAGES OF INSULIN THERAPIES IN TYPE I DIABETES

ADVANTAGES AND DISADVANTAGES OF INSULIN THERAPIES IN TYPE I DIABETES ADVANTAGES AND DISADVANTAGES OF INSULIN THERAPIES IN TYPE I DIABETES ABSTRACT Purpose The purpose of this paper is to investigate the advantages and disadvantages of using continuous subcutaneous insulin

More information

Issues in Emerging Health Technologies

Issues in Emerging Health Technologies Issues in Emerging Health Technologies Subcutaneous Open-loop Insulin Delivery for Type 1 Diabetes: Paradigm Real-Time System Issue 105 October 2007 Summary An open-loop insulin delivery system combines

More information

Diabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C

Diabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C Diabetes and Technology Rebecca Ray, MSN, APRN, FNP-C Insulin Pump Therapy and Continuous Glucose Monitoring In Patients with Type 2 Diabetes Page 1 Disclosures Certified Insulin Pump Trainer for: Animas

More information

2014 -- H 8166 S T A T E O F R H O D E I S L A N D

2014 -- H 8166 S T A T E O F R H O D E I S L A N D LC000 01 -- H 1 S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO INSURANCE - ACCIDENT AND SICKNESS INSURANCE POLICIES Introduced By: Representatives

More information

Diabetic Services, Supplies and Documentation. Presented by Medicare Part B and DME MAC Provider Outreach and Education (POE) January 2016

Diabetic Services, Supplies and Documentation. Presented by Medicare Part B and DME MAC Provider Outreach and Education (POE) January 2016 Diabetic Services, Supplies and Documentation Presented by Medicare Part B and DME MAC Provider Outreach and Education (POE) January 2016 DISCLAIMER This information release is the property of Noridian

More information

Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid

Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,

More information

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)

More information

Methods for Delivering Insulin and Monitoring Blood Sugar. A Review of the Research for Children, Teens, and Adults With Diabetes

Methods for Delivering Insulin and Monitoring Blood Sugar. A Review of the Research for Children, Teens, and Adults With Diabetes Methods for Delivering Insulin and Monitoring Blood Sugar A Review of the Research for Children, Teens, and Adults With Diabetes Is This Information Right for Me? Yes, if: Your doctor* has told you that

More information

INSULIN PRODUCTS. Jack DeRuiter

INSULIN PRODUCTS. Jack DeRuiter INSULIN PRODUCTS Jack DeRuiter The number and types of insulin preparations available in the United States is constantly changing, thus students should refer to recent drug resources for a current list

More information

Taking Insulin Pumps to School. Rachel Calendo, MS, RN, CPNP, CDE, Martha Cuevas, RN, BSN, CPT

Taking Insulin Pumps to School. Rachel Calendo, MS, RN, CPNP, CDE, Martha Cuevas, RN, BSN, CPT Taking Insulin Pumps to School Rachel Calendo, MS, RN, CPNP, CDE, Martha Cuevas, RN, BSN, CPT Insulin Pumps Today A micro-computer, about the size of a pager Programmed to deliver both a preset amount

More information

Mary Ann Vann MD Beth Israel Deaconess Medical Center Boston, MA

Mary Ann Vann MD Beth Israel Deaconess Medical Center Boston, MA Mary Ann Vann MD Beth Israel Deaconess Medical Center Boston, MA Presentation Focus SAMBA Consensus Statement VANN 2011 1 References Vann MA. Current Opinion in Anesthesiology. December 2009. Joshi GP,

More information

CURRENT THERAPEUTIC RESEARCH

CURRENT THERAPEUTIC RESEARCH CURRENT THERAPEUTIC RESEARCH VOLUME 70, NUMBER I, FEBRUARY 2009 Case Series Adjusting the Basal Insulin Regimen of Patients With Type 1 Diabetes Mellitus Receiving Insulin Pump Therapy During the Ramadan

More information

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each

More information

Insulin Administration: What You Don t Know May Hurt Your Patient

Insulin Administration: What You Don t Know May Hurt Your Patient Insulin Administration: What You Don t Know May Hurt Your Patient Jaime A. Davidson, MD, FACP, MACE Clinical Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Jaime A. Davidson,

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PC (CO) - Insulin Delivery Systems Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Insulin Delivery Systems Client: CO Approval Date:

More information

British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes

British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes Introduction Self-monitoring of blood glucose (SMBG) is in widespread use among

More information

Diabetes mellitus is a metabolic disorder of glucose metabolism with many causes and forms.

Diabetes mellitus is a metabolic disorder of glucose metabolism with many causes and forms. Chapter 20 Diabetes Mellitus Chapter 20 Lesson 20.1 Key Concept Diabetes mellitus is a metabolic disorder of glucose metabolism with many causes and forms. About Diabetes 20.8 million Americans have diabetes

More information

Use of Continuous Subcutaneous Insulin Infusion (CSII) Pumps in Hospitalized Patients Policy and Procedure

Use of Continuous Subcutaneous Insulin Infusion (CSII) Pumps in Hospitalized Patients Policy and Procedure Purpose: To ensure safe and accurate administration of insulin for patients using their own external continuous subcutaneous insulin infusion pump during hospitalization. Definitions: Insulin pump: An

More information

Modern Approaches to Transitions of Care in patients with Hyperglycemia in the Hospital Setting

Modern Approaches to Transitions of Care in patients with Hyperglycemia in the Hospital Setting Modern Approaches to Transitions of Care in patients with Hyperglycemia in the Hospital Setting Etie Moghissi, MD, FACE Clinical Associate Professor UCLA 1 Number (in Thousands) of Hospital Discharges

More information

Medications or therapeutic solutions may be injected directly into the bloodstream

Medications or therapeutic solutions may be injected directly into the bloodstream Intravenous Therapy Medications or therapeutic solutions may be injected directly into the bloodstream for immediate circulation and use by the body. State practice acts designate which health care professionals

More information

All Acute Care Hospitals and End-Stage Renal Disease Clinics. Subject: Billing and Claim Completion Guidelines for Renal Dialysis Services

All Acute Care Hospitals and End-Stage Renal Disease Clinics. Subject: Billing and Claim Completion Guidelines for Renal Dialysis Services Indiana Health Coverage Programs P R O V I D E R B U L L E T I N BT200223 MAY 29, 2002 To: All Acute Care Hospitals and End-Stage Renal Disease Clinics Subject: Billing and Claim Completion Guidelines

More information

Health Professional s. Guide to INSULIN PUMP THERAPY

Health Professional s. Guide to INSULIN PUMP THERAPY Health Professional s Guide to INSULIN PUMP THERAPY Table of Contents Introduction Presenting Insulin Pump Therapy to Your Patients When Your Patient Chooses the Pump Estimates for Starting Insulin Pump

More information

Insulin Pumps in Diabetes Management By Rita Carey Rubin, MS, RD, CDE. Suggested CDR Learning Codes: 5190, 5400, 5410, 5420; Level 2

Insulin Pumps in Diabetes Management By Rita Carey Rubin, MS, RD, CDE. Suggested CDR Learning Codes: 5190, 5400, 5410, 5420; Level 2 Insulin Pumps in Diabetes Management By Rita Carey Rubin, MS, RD, CDE Suggested CDR Learning Codes: 5190, 5400, 5410, 5420; Level 2 Controlling diabetes is one of the most important challenges facing patients

More information

Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol

Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding

More information

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl

More information

SCHOOL DISTRICT #22 VERNON DIABETES POLICY

SCHOOL DISTRICT #22 VERNON DIABETES POLICY SCHOOL DISTRICT #22 VERNON DIABETES POLICY A student with diabetes does not automatically qualify for additional support. The student may qualify as a temporary D category (chronic health) after diagnosis

More information

There seem to be inconsistencies regarding diabetic management in

There seem to be inconsistencies regarding diabetic management in Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional

More information

Causes, incidence, and risk factors

Causes, incidence, and risk factors Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,

More information

A guidebook for people with diabetes

A guidebook for people with diabetes A guidebook for people with diabetes This booklet is designed to supplement, not replace, your doctor s advice. Please consult your doctor if you have any questions about what you read. You ll learn how

More information